Orris

post antibiotics effect

The post-antibiotic effect (PAE) is the persistent suppression of bacterial growth that continues even after antibiotic concentrations fall below the minimum inhibitory concentration (MIC). It reflects residual drug-bacteria interaction at the ribosomal or DNA level, and is used to guide dosing intervals.
Searching sources...
Reading File
Searching the Web

post-antibiotic effect mechanism clinical significance

Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Here is a thorough breakdown of the Post-Antibiotic Effect (PAE):

Post-Antibiotic Effect (PAE)

Definition

PAE is the persistent suppression of bacterial growth that continues after antibiotic concentrations fall below the Minimum Inhibitory Concentration (MIC). It reflects lingering bacteriostatic or bactericidal activity even when the drug is no longer present at inhibitory levels.
Mathematical Formula:
PAE = T - C
  • T = time for the viable bacterial count in the drug-exposed culture to increase 10-fold above the count immediately after drug removal
  • C = time for the count in an untreated control culture to increase 10-fold
The PAE thus quantifies how long bacteria are delayed in returning to logarithmic growth after drug exposure.
(Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 1417)

Proposed Mechanisms

Three main mechanisms have been identified:
  1. Slow recovery from reversible, non-lethal damage to bacterial cell structures (e.g., membrane disruption, ribosomal injury)
  2. Persistence of the drug at a binding site or within the periplasmic space, continuing to exert effect even after serum levels drop
  3. Need to synthesize new enzymes before bacterial growth can resume (e.g., after drug has inhibited transcription or translation machinery)
(Katzung's, p. 1417-1418)

In Vitro vs. In Vivo PAE

SettingDuration
In vitroShorter
In vivoLonger (often significantly)
Why is in vivo PAE longer? Two additional factors amplify PAE in the body:
  • Post-Antibiotic Leukocyte Enhancement (PALE): Bacteria weakened by the antibiotic are more susceptible to phagocytosis by white blood cells
  • Subinhibitory antibiotic concentrations: Even after falling below MIC, residual drug concentrations continue to contribute to bacterial suppression

Relationship to Kill Characteristics

Kill PatternPAE
Concentration-dependent (aminoglycosides, fluoroquinolones)Strong, prolonged PAE
Time-dependent (beta-lactams, carbapenems)Minimal to moderate PAE
AUC/MIC-dependent (vancomycin, daptomycin)Variable
Note: Macrolides (e.g., azithromycin) are an exception - they are time-dependent killers but have a long PAE, likely because they suppress bacterial growth rather than causing cell lysis. (Goldman-Cecil Medicine)

Antibiotics with PAE >= 1.5 Hours (In Vitro)

Against Gram-Positive Cocci: Aminoglycosides, Carbapenems, Cephalosporins, Chloramphenicol, Clindamycin, Daptomycin, Glycopeptides (vancomycin), Ketolides, Macrolides, Oxazolidinones, Penicillins, Quinolones, Rifampin, Streptogramins, Sulfonamides, Tetracyclines, Tigecycline, Trimethoprim
Against Gram-Negative Bacilli (more selective): Aminoglycosides, Carbapenems, Chloramphenicol, Quinolones, Rifampin, Tetracyclines, Tigecycline
(Katzung's, p. 1418)

Clinical Significance - Dosing Implications

The PAE is a key pharmacodynamic concept that directly informs dosing schedules:
  1. Once-daily aminoglycosides: Exploit both concentration-dependent killing and prolonged PAE. A high peak dose achieves maximal bacterial kill; then the PAE maintains suppression even as serum levels drop below MIC. This also reduces the trough concentration, minimizing nephrotoxicity. (Goodman & Gilman's; Fishman's Pulmonary Diseases, p.)
  2. Fluoroquinolones: Concentration-dependent PAE against both Gram-positive and Gram-negative organisms allows once- or twice-daily dosing.
  3. Beta-lactams: Have minimal or no PAE against Gram-negatives. Therefore, they must be dosed frequently or given as continuous/extended infusions to keep concentrations above MIC throughout the dosing interval.
  4. Rifampin: Shows long, concentration-dependent PAE because its macrocyclic ring binds stably and irreversibly to the beta subunit of DNA-dependent RNA polymerase (rpoB) - the complex is slowly reversed. (Goodman & Gilman's, p. 1152)
  5. TB intermittent dosing: Takes advantage of the slow growth of M. tuberculosis and PAE of anti-TB drugs to allow intermittent regimens (though acquired resistance is a risk, especially in HIV). (Fishman's)

Post-Antibiotic Sub-MIC Effect (PA SME)

A related concept - bacteria exposed to sub-inhibitory concentrations of antibiotics (concentrations below MIC but above zero) after a full drug exposure show enhanced susceptibility to the drug. This further extends the effective duration of bacterial suppression beyond even the PAE window.

Summary Table

FeatureDetails
DefinitionPersistent bacterial suppression after drug falls below MIC
FormulaPAE = T - C
MechanismsCell structure damage, drug persistence at binding site, need for new enzyme synthesis
Strongest PAEAminoglycosides, Fluoroquinolones, Rifampin
Weakest PAE vs. GNRBeta-lactams (penicillins, cephalosporins)
In vivo amplifiersPALE (leukocyte enhancement), sub-MIC residual drug
Clinical useGuides once-daily dosing; extends dosing intervals safely

MOA of chloroquine

Chloroquine is a 4-aminoquinoline antimalarial that works primarily by accumulating in the acidic food vacuole of Plasmodium and inhibiting the detoxification of heme (ferriprotoporphyrin IX) released during hemoglobin digestion, leading to toxic heme accumulation that kills the parasite.
Searching sources...
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Loading Image
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here is a detailed breakdown of the Mechanism of Action of Chloroquine, sourced from authoritative pharmacology textbooks:

Mechanism of Action of Chloroquine

Drug Class

Chloroquine is a synthetic 4-aminoquinoline that acts primarily on the erythrocytic (blood) stage of Plasmodium infection.

Step-by-Step Mechanism

Action of chloroquine on hemozoin formation by Plasmodium
Figure: Action of chloroquine on the formation of hemozoin by Plasmodium species (Lippincott Pharmacology)
Step 1 - Hemoglobin digestion: The Plasmodium parasite (inside the red blood cell) digests the host cell's hemoglobin in its food vacuole to obtain the essential amino acids it needs for growth and replication.
Step 2 - Toxic heme release: This digestion releases large amounts of free heme (ferriprotoporphyrin IX), which is highly toxic to the parasite itself - it disrupts membranes and generates reactive oxygen species.
Step 3 - Normal parasite defense (hemozoin formation): To protect itself, the parasite normally polymerizes heme into hemozoin (malaria pigment) - a non-toxic, insoluble crystal that is safely sequestered within the food vacuole.
Step 4 - Chloroquine's action: Chloroquine, being a diprotic weak base, enters the erythrocyte and crosses into the parasite. It becomes ion-trapped and concentrated in the acidic food vacuole (pH ~5.0), reaching concentrations many times higher than in the plasma. There, it binds specifically to free heme, physically blocking its polymerization into hemozoin.
Result:
  • Free heme accumulates in the food vacuole
  • Heme causes oxidative damage to the phospholipid membranes
  • This leads to lysis of both the parasite and the red blood cell
(Lippincott Illustrated Reviews: Pharmacology, p. 1170-1171)

Key Pharmacodynamic Concept: Ion Trapping

Chloroquine is a weak diprotic base (pKa ~8.1 and 10.2). In the acidic food vacuole of the parasite:
  • It becomes di-protonated (charged)
  • Charged molecules cannot cross lipid membranes back out
  • This results in concentration 1000x higher inside the vacuole than in the surrounding cytoplasm
This ion-trapping mechanism is also responsible for raising the pH of the vacuole, which itself impairs hemoglobin digestion.

Additional MOA: Immunomodulation (Non-malarial Uses)

When used in autoimmune diseases (SLE, rheumatoid arthritis), chloroquine and its analogue hydroxychloroquine work by:
  • Inhibiting lysosomal enzymes - by raising lysosomal pH, it impairs antigen processing and presentation
  • Blocking Toll-like receptor (TLR) signaling - particularly TLR7 and TLR9, which recognize nucleic acids and drive autoimmune inflammation
  • Suppressing pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha) by inhibiting cytokine release from monocytes
  • Reducing antigen-antibody complex formation and complement activation
(Firestein & Kelley's Textbook of Rheumatology)

Resistance Mechanism

P. falciparum resistance to chloroquine is due to mutations in the PfCRT gene (Plasmodium falciparum Chloroquine Resistance Transporter). The mutant CRT protein pumps chloroquine out of the food vacuole, preventing it from accumulating to toxic concentrations. This is the primary mechanism behind widespread chloroquine resistance, now seen in almost all malaria-endemic areas.

Summary Table

FeatureDetail
Drug class4-aminoquinoline
Target stageErythrocytic (blood) stage of Plasmodium
Site of actionAcidic food vacuole of the parasite
Primary targetHeme polymerization (hemozoin formation)
Key mechanismIon trapping → heme accumulation → oxidative membrane lysis
Secondary (autoimmune)Lysosomal pH raising, TLR inhibition, cytokine suppression
ResistancePfCRT mutation - efflux pump removes drug from food vacuole
Active againstP. vivax, P. ovale, P. malariae; NOT resistant P. falciparum

can beta blockers in give in ccf

Yes, beta-blockers can and should be given in chronic congestive cardiac failure (CCF/HFrEF) - but they are contraindicated in acute decompensated heart failure. This was once controversial, but large trials (MERIT-HF, CIBIS-II, COPERNICUS) firmly established their mortality benefit.
Searching sources...
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
attachment
attachment

question 3

The question asks: "Can Beta blockers be used in this patient? Explain giving reason." (2 marks) — from a case of CCF with dilated cardiomyopathy, EF 30%.
Searching sources...
Finding Sources
Finding Sources
Reading File
Finding Sources
Here is the model answer for Question 4, Sub-question 3:

Q. Can Beta-blockers be used in this patient? Explain giving reason. (2 marks)

Answer: YES - Beta-blockers CAN be used in this patient.

The Patient's Diagnosis:

  • CCF (Congestive Cardiac Failure) due to dilated cardiomyopathy
  • EF = 30% (severely reduced - HFrEF: Heart Failure with reduced Ejection Fraction)
  • This is chronic, stable heart failure - NOT acute decompensation

Reason WHY Beta-blockers are Used:

Pathophysiological basis:
In CCF, the failing heart triggers compensatory sympathetic nervous system activation, causing a surge in circulating catecholamines (norepinephrine, epinephrine). While this initially supports cardiac output, chronic catecholamine excess is directly cardiotoxic - it causes:
  • Myocyte hypertrophy and apoptosis
  • Beta-1 receptor downregulation
  • Worsening ventricular remodeling
  • Arrhythmias and sudden cardiac death
Beta-blockers block these toxic catecholamine effects, thereby slowing or reversing ventricular remodeling.
(Katzung's Basic & Clinical Pharmacology, 16th Ed., p. 345)

Clinical Evidence:

Three landmark trials firmly established mortality benefit:
TrialDrugResult
MERIT-HFMetoprolol succinate~34% reduction in all-cause mortality
CIBIS-IIBisoprolol~34% reduction in all-cause mortality
COPERNICUSCarvedilol~35% reduction in all-cause mortality (even in severe HF, EF <25%)

Approved Beta-blockers for CCF (NOT a class effect):

Only three beta-blockers have proven mortality benefit in HFrEF:
  1. Carvedilol (non-selective BB + alpha-1 blocker) - also reduces afterload
  2. Bisoprolol (selective beta-1 blocker)
  3. Metoprolol succinate (extended-release, selective beta-1)
  4. Nebivolol (beta-1 selective + nitric oxide-mediated vasodilation) - especially in elderly

Important Conditions for Use:

  • Must be started at very low doses and titrated slowly upward
  • Patient must be hemodynamically stable (no acute decompensation, no pulmonary edema)
  • NOT given in acute decompensated heart failure (can precipitate cardiogenic shock)
  • Several months of therapy required before improvement in EF and symptoms is seen

One-line Exam Answer:

Yes, beta-blockers (carvedilol/bisoprolol/metoprolol succinate) can be used in this patient's chronic CCF with reduced EF, because they block the cardiotoxic effects of chronic sympathetic overactivation, reduce ventricular remodeling, improve EF, and significantly reduce mortality - provided they are started at low doses in a hemodynamically stable patient.
This is a shared conversation. Sign in to Orris to start your own chat.